إعلان
إعلان

TEVA

TEVA logo

Teva Pharmaceutical Industries Limited - ADR

32.40
USD
برعاية
+0.28
+0.88%
٠٧ يناير, ١٦:٠٠ UTC -5
مغلق
exchange

قبل الإفتتاح

32.71

+0.31
+0.96%

تقارير أرباح TEVA

النسبة الإيجابية المفاجئة

TEVA تفوق 13 من 28 آخر التقديرات.

46%

التقرير التالي

بيانات التقرير القادم
٢٨ يناير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$4.49B
/
$0.70
التغير الضمني من Q3 25 (Revenue/ EPS)
+0.31%
/
-10.26%
التغير الضمني من Q4 24 (Revenue/ EPS)
+6.27%
/
-1.41%

Teva Pharmaceutical Industries Limited - ADR earnings per share and revenue

On ٠٥ نوفمبر ٢٠٢٥, TEVA reported earnings of 0.78 USD per share (EPS) for Q3 25, beating the estimate of 0.66 USD, resulting in a 16.50% surprise. Revenue reached 4.48 مليار, compared to an expected 4.44 مليار, with a 0.91% difference. The market reacted with a +20.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 المحللين forecast an EPS of 0.70 USD, with revenue projected to reach 4.49 مليار USD, implying an نقصان of -10.26% EPS, and زيادة of 0.31% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Teva Pharmaceutical Industries Limited - ADR reported EPS of $0.78, beating estimates by 16.5%, and revenue of $4.48B, 0.91% above expectations.
The stock price moved up 20.23%, changed from $20.46 before the earnings release to $24.60 the day after.
The next earning report is scheduled for ٢٨ يناير ٢٠٢٦.
Based on 6 المحللين, Teva Pharmaceutical Industries Limited - ADR is expected to report EPS of $0.70 and revenue of $4.49B for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان